Literature DB >> 7809116

Hematopoietic development of vav-/- mouse embryonic stem cells.

R Zhang1, F Y Tsai, S H Orkin.   

Abstract

The vav protooncogene product is expressed nearly exclusively in hematopoietic lineages and contains several structural motifs (SH2/SH3 domains and a dbl-oncogene homology region) typical of proteins functioning in signaling pathways. To ascertain if vav expression is required for hematopoiesis we generated vav-negative mouse embryonic stem cells by gene targeting and examined the consequences of loss of vav function on erythroid and myeloid development in vitro and in vivo. In conflict with the conclusions drawn from expression of antisense vav RNA in embryonic stem cells [Wulf, G. M., Adra, C. N. & Lim, B. (1993) EMBO J. 12, 5065-5074], we observed erythroid and myeloid development in the absence of vav. These experiments demonstrate that vav expression is not absolutely required for hematopoietic development.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7809116      PMCID: PMC45518          DOI: 10.1073/pnas.91.26.12755

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

Review 1.  vav: a molecule for all haemopoiesis?

Authors:  S Katzav
Journal:  Br J Haematol       Date:  1992-06       Impact factor: 6.998

2.  Production of homozygous mutant ES cells with a single targeting construct.

Authors:  R M Mortensen; D A Conner; S Chao; A A Geisterfer-Lowrance; J G Seidman
Journal:  Mol Cell Biol       Date:  1992-05       Impact factor: 4.272

3.  Proto-vav and gene expression.

Authors:  M S Boguski; A Bairoch; T K Attwood; G S Michaels
Journal:  Nature       Date:  1992-07-09       Impact factor: 49.962

4.  Early fetal hematopoietic development from in vitro differentiated embryonic stem cells.

Authors:  U Burkert; T von Rüden; E F Wagner
Journal:  New Biol       Date:  1991-07

5.  Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene.

Authors:  V L Tybulewicz; C E Crawford; P K Jackson; R T Bronson; R C Mulligan
Journal:  Cell       Date:  1991-06-28       Impact factor: 41.582

6.  The hematopoietically expressed vav proto-oncogene shares homology with the dbl GDP-GTP exchange factor, the bcr gene and a yeast gene (CDC24) involved in cytoskeletal organization.

Authors:  J M Adams; H Houston; J Allen; T Lints; R Harvey
Journal:  Oncogene       Date:  1992-04       Impact factor: 9.867

7.  Hematopoietic development of embryonic stem cells in vitro: cytokine and receptor gene expression.

Authors:  R M Schmitt; E Bruyns; H R Snodgrass
Journal:  Genes Dev       Date:  1991-05       Impact factor: 11.361

8.  Tyrosine phosphorylation of vav proto-oncogene product containing SH2 domain and transcription factor motifs.

Authors:  B Margolis; P Hu; S Katzav; W Li; J M Oliver; A Ullrich; A Weiss; J Schlessinger
Journal:  Nature       Date:  1992-03-05       Impact factor: 49.962

9.  Tyrosine phosphorylation of the vav proto-oncogene product in activated B cells.

Authors:  X R Bustelo; M Barbacid
Journal:  Science       Date:  1992-05-22       Impact factor: 47.728

10.  Product of vav proto-oncogene defines a new class of tyrosine protein kinase substrates.

Authors:  X R Bustelo; J A Ledbetter; M Barbacid
Journal:  Nature       Date:  1992-03-05       Impact factor: 49.962

View more
  8 in total

Review 1.  Regulatory and signaling properties of the Vav family.

Authors:  X R Bustelo
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

2.  Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation.

Authors:  L Zeng; P Sachdev; L Yan; J L Chan; T Trenkle; M McClelland; J Welsh; L H Wang
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

3.  A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development.

Authors:  C K Qu; Z Q Shi; R Shen; F Y Tsai; S H Orkin; G S Feng
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

4.  Targeted null-mutation in the vascular endothelial-cadherin gene impairs the organization of vascular-like structures in embryoid bodies.

Authors:  D Vittet; T Buchou; A Schweitzer; E Dejana; P Huber
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

5.  Mast Cell Activation and KSHV Infection in Kaposi Sarcoma.

Authors:  Leona W Ayers; Arturo Barbachano-Guerrero; Shane C McAllister; Julie A Ritchie; Elizabeth Asiago-Reddy; Linda C Bartlett; Ethel Cesarman; Dongliang Wang; Rosemary Rochford; Jeffrey N Martin; Christine A King
Journal:  Clin Cancer Res       Date:  2018-07-03       Impact factor: 12.531

6.  Targeted disruption of the NIT8 gene in Chlamydomonas reinhardtii.

Authors:  J A Nelson; P A Lefebvre
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

Review 7.  Genetic knockouts in mice: an update.

Authors:  B S Shastry
Journal:  Experientia       Date:  1995-11-15

8.  A critical role for mTORC1 in erythropoiesis and anemia.

Authors:  Zachary A Knight; Sarah F Schmidt; Kivanc Birsoy; Keith Tan; Jeffrey M Friedman
Journal:  Elife       Date:  2014-09-08       Impact factor: 8.140

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.